ArticleChemical science2020
A straightforward approach to antibodies recognising cancer specific glycopeptidic neoepitopes.
Article in Chemical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Structural Basis of a High-Affinity Antibody Binding to Glycoprotein with Glycocalyx Decay.JACS Au · 2026Article
- Using Synthetic Glycans to Investigate Anti-Glycan Antibodies and Explore Their Medical Potential.Angewandte Chemie (International ed. in English) · 2026Review
- Structure of the Fab fragment of a humanized 5E5 antibody to a cancer-specific Tn-MUC1 epitope.Acta crystallographica. Section D, Structural biology · 2025Article
- Exploring the Conformational Changes and Dynamics of Mucins in Their Free State and in Complex with Mucin-Binding Proteins Using NMR.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Reverse-engineering the anti-MUC1 antibody 139H2 by mass spectrometry-based de novo sequencing.Life science alliance · 2024Article
- Targeting Siglec-Sialylated MUC1 Immune Axis in Cancer.Cancers · 2024Review
- Structural and molecular insight into antibody recognition of dynamic neoepitopes in membrane tethered MUC1 of pancreatic cancer cells and secreted exosomes.RSC chemical biology · 2023Article
- Molecular Recognition of GalNAc in Mucin-Type O-Glycosylation.Accounts of chemical research · 2023Review
- Synthesis and biomedical applications of mucin mimic materials.Advanced drug delivery reviews · 2022Review
- Development of a GalNAc-Tyrosine-Specific Monoclonal Antibody and Detection of TyrosineJournal of the American Chemical Society · 2022Article
- Selective reaction monitoring approach using structure-defined synthetic glycopeptides for validating glycopeptide biomarkers pre-determined by bottom-up glycoproteomics.RSC advances · 2022Article
- Exploring Molecular Contacts of MUC1 at CIN85 Binding Interface to Address Future Drug Design Efforts.International journal of molecular sciences · 2021Article
- Case Report: Significant Efficacy of Pyrotinib in the Treatment of Extensive Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Cutaneous Metastases: A Report of Five Cases.Frontiers in oncology · 2021Article
- Potential of Anti-MUC1 Antibodies as a Targeted Therapy for Gastrointestinal Cancers.Vaccines · 2020Review
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrantly truncated immature
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.